Company: PIII
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001628280-25-015305
Chunk: 214

Company: P3 Health Partners Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 7
Chunk 214
---
— Granted$0.73 4,400 Non-vested as of December 31, 2024$0.73 4,400The following additional disclosures are provided for RSU awards:Year EndedDecember 31, 2024Weighted average grant date fair value$0.73 The RSU award will be subject to both service-vesting and performance-vesting conditions, such that both conditions must be satisfied for the RSUs to vest. The applicable vesting date will be the later of the date on which the applicable “service-vesting condition” is satisfied and the date on which the “performance-vesting condition” is satisfied. The service-vesting condition will be satisfied (i) with respect to 25% of the underlying shares on the first anniversary of the effective date of employment, and (ii) as to the remaining 75% of the underlying shares, in substantially equal installments on each quarterly anniversary over the three-year period thereafter. The performance-vesting condition will be satisfied upon the closing of the first underwritten offering and sale of the Company’s Class A common stock following the effective date of employment, subject to continued employment through such date. As of December 31, 2024, total equity-based compensation cost related to all unvested RSUs under the 2024 Plan was $2.7 million, which is expected to be recognized over a weighted average period of 3.4 years.Compensation ExpenseEquity-based compensation recorded within corporate, general and administrative expense on the consolidated statements of operations was $5.8 million and $6.0 million during the years ended December 31, 2024 and 2023, respectively.The Company did not recognize any tax benefits related to equity-based compensation for the years ended December 31, 2024 and 2023.

P3 Health Partners Inc. | 2024 Form 10-K | 114

Note 16: Net Loss per Share

The following table provides the computation of basic and diluted net loss per share:Year Ended December 31,20242023(in thousands, except per share data)Numerator–basic:Net loss attributable to Class A common stockholders–basic$(135,849)$(57,773)Numerator–diluted:Net loss attributable to Class A common stockholders–basic$(135,849)$(57,773)Effective of dilutive securities:Shares of Class V common stock— (128,